TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06983743: A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

Sponsor: Erasca, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 600 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06983743 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06983743 Rescue Dossier →